Cargando…

Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients

BACKGROUND: Belatacept (Bela) was developed to reduce nephrotoxicity and cardiovascular risk that are associated with the chronic use of Calcineurin inhibitors (CNIs) in kidney transplant recipients. The use of Bela with early steroid withdrawal (ESW) and simultaneous CNI avoidance has not been form...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tawhari, Ibrahim, Hallak, Patrick, Bin, Sofia, Yamani, Fatmah, Safar-Boueri, Maria, Irshad, Aazib, Leventhal, Joseph, Ansari, Mohammed Javeed, Cravedi, Paolo, Gallon, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806416/ https://www.ncbi.nlm.nih.gov/pubmed/36601111 http://dx.doi.org/10.3389/fimmu.2022.1096881

Ejemplares similares

Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters
por: Terrec, Florian, et al.
Publicado: (2019)

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial
por: Bredewold, Obbo W., et al.
Publicado: (2022)

Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept
por: Choi, Mira, et al.
Publicado: (2020)

Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants
por: Kumar, Dhiren, et al.
Publicado: (2017)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

Belatacept conversion in African American kidney transplant recipients with severe renal dysfunction
por: Snyder, Heather S, et al.
Publicado: (2016)

Cellular and molecular immune profiles in renal transplant recipients after conversion from Tacrolimus to Sirolimus
por: Gallon, Lorenzo, et al.
Publicado: (2014)

Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome
por: Tatapudi, Vasishta S., et al.
Publicado: (2018)

Three-Year Outcomes in Kidney Transplant Recipients Switched From Calcineurin Inhibitor-Based Regimens to Belatacept as a Rescue Therapy
por: Morel, Antoine, et al.
Publicado: (2022)

Belatacept Conversion in Kidney After Liver Transplantation
por: Cristea, Octav, et al.
Publicado: (2021)

Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen—Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil
por: Traitanon, Opas, et al.
Publicado: (2019)

Pilot Analysis of Late Conversion to Belatacept in Kidney Transplant Recipients for Biopsy-Proven Chronic Tacrolimus Toxicity
por: Gupta, Shruti, et al.
Publicado: (2018)

Time-Limited Therapy with Belatacept in Kidney Transplant Recipients
por: Letellier, Thibault, et al.
Publicado: (2022)

Preservation of Antiviral Immunologic Efficacy Without Alloimmunity After Switch to Belatacept in Calcineurin Inhibitor–Intolerant Patients
por: Schaenman, Joanna, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

Conversion to belatacept after lung transplantation: Report of 10 cases
por: Brugière, Olivier, et al.
Publicado: (2023)

A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants
por: Mathew, James M., et al.
Publicado: (2018)

De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019)

Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients
por: El Sakhawi, Karim, et al.
Publicado: (2020)

Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept
por: Schwarz, Chloë, et al.
Publicado: (2023)

Optimization of de novo belatacept‐based immunosuppression administered to renal transplant recipients
por: Kirk, Allan D., et al.
Publicado: (2020)

Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients
por: Gouin, Anna, et al.
Publicado: (2020)

Assessment of Renal Transplant Perfusion by Contrast-Enhanced Ultrasound after Switch from Calcineurin Inhibitor to Belatacept: A Pilot Study
por: Osmanodja, Bilgin, et al.
Publicado: (2022)

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study
por: Bremer, Sara, et al.
Publicado: (2009)

Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
por: Coscia, Lisa, et al.
Publicado: (2023)

Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors
por: Yu, Ji Hyun, et al.
Publicado: (2016)

Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients
por: Pacheco, Larissa Sgaria, et al.
Publicado: (2018)

Belatacept: Good, but not good enough?
por: Parameswaran, Sreejith, et al.
Publicado: (2012)

Belatacept: the challenges with transformational drugs
por: Vincenti, Flavio
Publicado: (2017)

Phase I study of single‐dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients
por: Moudgil, Asha, et al.
Publicado: (2019)

Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate
por: Belliere, Julie, et al.
Publicado: (2014)

Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France
por: Bertrand, Dominique, et al.
Publicado: (2023)

Belatacept associated - cytomegalovirus retinitis in a kidney transplant recipient: a case report and review of the literature
por: Deliège, Pierre-Guillaume, et al.
Publicado: (2020)

Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept
por: Chavarot, Nathalie, et al.
Publicado: (2021)

Belatacept: A worthy alternative to cyclosporine?
por: Melvin, George, et al.
Publicado: (2012)

Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014)

Belatacept in renal transplantation—quo vadis?
por: Westhoff, Timm H.
Publicado: (2016)

Calcineurin inhibitor toxicity in a renal transplant recipient
por: Charney, Douglas A., et al.
Publicado: (2009)

Three-year Outcomes After Conversion From Monthly to Every 2-month Belatacept Maintenance Therapy in Kidney Transplant Recipients: Results From a Randomized Controlled Trial
por: Johnson, Aileen C., et al.
Publicado: (2023)

Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients
por: Kaplan, Adam, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0bhsa12vued9qd2csd03nam1am